GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
CONCLUSION: GLP-1RAs, precisely longer acting formulations, reduced ischemic cerebrovascular events in T2DM. Observed benefits were significantly higher in patients with shorter T2DM duration and higher eGFR.PMID:36800286 | DOI:10.1210/clinem/dgad076
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Mainak Banerjee Rimesh Pal Satinath Mukhopadhyay Kirthana Nair Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Hemorrhagic Stroke | Ischemic Stroke | Science | Statistics | Stroke | Websites